KR970707155A - Human stanniocalcin-alpha - Google Patents

Human stanniocalcin-alpha

Info

Publication number
KR970707155A
KR970707155A KR1019970703099A KR19970703099A KR970707155A KR 970707155 A KR970707155 A KR 970707155A KR 1019970703099 A KR1019970703099 A KR 1019970703099A KR 19970703099 A KR19970703099 A KR 19970703099A KR 970707155 A KR970707155 A KR 970707155A
Authority
KR
South Korea
Prior art keywords
polypeptide
polynucleotide
staniocalcin
alpha
acid sequence
Prior art date
Application number
KR1019970703099A
Other languages
Korean (ko)
Other versions
KR100432260B1 (en
Inventor
헨릭 올젠
로버트 디 프레이취맨
Original Assignee
벤슨 로버트 에이치
휴먼 게놈 사이언시즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 벤슨 로버트 에이치, 휴먼 게놈 사이언시즈, 인코포레이티드 filed Critical 벤슨 로버트 에이치
Publication of KR970707155A publication Critical patent/KR970707155A/en
Application granted granted Critical
Publication of KR100432260B1 publication Critical patent/KR100432260B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Nutrition Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 사람 스탄니오칼신-알파 폴리펩타이드, 이와 같은 폴리펩타이드를 암호화하는 DNA(RNA) 및 재조합 기술에 의해 이와 같은 폴리펩타이드를 제조하는 방법에 관한 것이다. 또한, 본 발명에는 이와 같은 폴리펩타이드를 사용하여 신장, 골 및 심장 질환 및 골다공증 및 페제트병을 유도하는 전해질 이상을 치료하는 방법이 기술되어 있다. 또한, 이와 같은 폴리펩타이트에 대한 길항제, 및 저칼슘혈증 및 골다공증을 치료학적으로 치료하기 위한 이들의 용도가 기술되어 있다. 또한, 스탄니오칼신-알파 서열의 변이된 형태와 관련된 질환 및 질환에 대한 민감성을 검출하기 위한 진단약으로서의 스탄니오칼신-알파 서열의 용도가 기술되어 있다.The present invention relates to human staniocalcin-alpha polypeptides, DNA (RNA) encoding such polypeptides and methods of making such polypeptides by recombinant techniques. Also described herein are methods for using such polypeptides to treat electrolyte, bone and heart disease and electrolyte abnormalities leading to osteoporosis and Peget's disease. In addition, antagonists against such polypeptides and their use for the therapeutic treatment of hypocalcemia and osteoporosis are described. Also described is the use of staniocalcin-alpha sequence as a diagnostic agent for detecting sensitivity to diseases and disorders associated with mutated forms of staniocalcin-alpha sequence.

Description

사람 스탄니오칼신-알파(Human stanniocalcin-alpha)Human stanniocalcin-alpha

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음As this is a public information case, the full text was not included.

Claims (22)

(a) 제1도는 추정된 아미노산 서열을 갖는 폴리펩타이드 또는 이의 단편, 동족체 또는 유도체를 암호화하는 폴리뉴클레오타이드; (b) ATCC 기탁번호 제75831호에 함유된 cDNA에 의해 암호화된 아미노산 서열을 갖는 폴리펩타이드 또는 이의 단편, 동족체 또는 유도체를 암호화하는 폴리뉴클레오타이드로 이루어진 그룹중에서 선택된 분리된 폴리뉴클레오타이드.(a) FIG. 1 is a polynucleotide encoding a polypeptide having a presumed amino acid sequence or a fragment, homologue or derivative thereof; (b) an isolated polynucleotide selected from the group consisting of a polypeptide having an amino acid sequence encoded by a cDNA contained in ATCC Accession No. 75831 or a polynucleotide encoding a fragment, homologue or derivative thereof. 제1항에 있어서, DNA인 폴리뉴클레오타이드.The polynucleotide of claim 1, wherein the polynucleotide is DNA. 제1항에 있어서, RNA인 폴리뉴클레오타이드.The polynucleotide of claim 1, which is RNA. 제1항에 있어서, 게놈 DNA인 폴리뉴클레오타이드.The polynucleotide of claim 1, wherein the polynucleotide is genomic DNA. 제2항에 있어서, 제1도의 추정된 아미노산 서열을 갖는 폴리펩타이드를 암호화하는 폴리뉴클레오타이드.3. The polynucleotide of claim 2 encoding a polypeptide having the estimated amino acid sequence of FIG. 제2항에 있어서, ATCC 기탁번호 제75831호의 cDNA에 의해 암호화된 폴리펩타이드를 암호화하는 폴리뉴클레오타이드.The polynucleotide of claim 2, which encodes a polypeptide encoded by the cDNA of ATCC Accession No. 75831. 제1항에 있어서, 제1도에 도시된 폴리펩타이드에 대한 암호화 서열을 갖는 폴리뉴클레오타이드.The polynucleotide of claim 1 having a coding sequence for the polypeptide shown in FIG. 1. 제2항의 DNA를 함유하는 벡터.A vector containing the DNA of claim 2. 제8항의 벡터로 유전 공항적으로 조작된 숙주 세포.A host cell genetically engineered with the vector of claim 8. 제9항의 숙주 세포토로부터 DNA에 의해 암호화된 폴리펩타이드를 발현시킴을 포함하는 폴리펩타이드의 제조방법.A method for producing a polypeptide comprising expressing a polypeptide encoded by DNA from a host cell soil of claim 9. 제8항의 벡터로 세포를 유전 공학적으로 조작시킴을 포함하여, 폴리펩타이드를 발현시킬 수 있는 세포를 제조하는 방법.A method of producing a cell capable of expressing a polypeptide, including genetically engineering the cell with the vector of claim 8. 사람 스탄니오칼신-알파 활성을 갖는 폴리펩타이드를 암호화하는, 제2항의 DNA와 하이브리드화 가능한 분리된 DNA.An isolated DNA capable of hybridizing with the DNA of claim 2, which encodes a polypeptide having human staniocalcin-alpha activity. (i) 제1도의 추정된 아미노산을 서열을 갖는 폴리펩타이드 및 이의 단편, 동족체 및 유도체 및 (ii) ATCC 기탁번호 제75831호의 cDNA에 의해 암호화된 폴리펩타이드 및 이의 단편, 동족체 및 유도체로 이루어진 그룹 중에서 선택된 폴리펩타이드.(i) a polypeptide consisting of the amino acid sequence of FIG. Selected polypeptides. 제13항에 있어서, 제1도의 추정된 아미노산 서열을 갖는 폴리펩타이드.The polypeptide of claim 13 having the estimated amino acid sequence of FIG. 1. 제13항의 폴리펩타이드에 대한 항체.An antibody against the polypeptide of claim 13. 제13항의 폴리펩타이드에 대한 길항체.An antagonist of the polypeptide of claim 13. 제13항의 폴리펩타이드에 대한 효능제.An agonist for the polypeptide of claim 13. 사람 스탄니오칼신-알파를 필요로 하는 환자에게 치료학적 유효량의 제13항의 폴리펩타이드를 투여함을 포함하는 상기 환자의 치료 방법.A method of treating a patient comprising administering a therapeutically effective amount of the polypeptide of claim 13 to a patient in need of human staniocalcin-alpha. 스탄니오칼신-알파를 억제시킬 필요가 있는 환자에게 치료학적 유효량의 제16항의 길항제를 투여함을 포함하는 상기 환자의 치료 방법.A method of treating a patient comprising administering to the patient in need thereof a therapeutically effective amount of the antagonist of claim 16. 제18항에 있어서, 환자에게 폴리펩타이드를 암호화하는 DNA를 제공하여 상기 폴리펩타이드를 생체내에서 발현시킴으로써 치료학적으로 유효량의 폴리펩타이드를 투여하는 방법.The method of claim 18, wherein the patient is administered a therapeutically effective amount of the polypeptide by providing DNA encoding the polypeptide to express the polypeptide in vivo. 세포 표면상에 스탄니오칼신-알파 수용체를 발현시키는 포유동믈 세포를 제조하고; 스탄니오칼신-알파의 존재 또는 부재하에서 포유동물 세포, 표지된 칼슘 및 스크리닝시키고자 하는 화합물을 배합하며; 당해화합물이 칼슘 흡수를 자극하거나 억제시키는가의 여부를 측정하는 단계를 포함하여, 효능제 및 길항체를 확인하는 방법.Preparing mammalian cells expressing staniocalcin-alpha receptor on the cell surface; Combining mammalian cells, labeled calcium and the compound to be screened in the presence or absence of staniocalcin-alpha; A method of identifying agonists and antagonists comprising determining whether the compound stimulates or inhibits calcium absorption. 숙주에서 유도된 샘플로부터 사람 스탄니오칼신-알파를 암호화하는 핵산 서열을 분리하고, 사람 스탄니오칼신-알파 핵산 서열에서 돌연변이를 측정하는 단계를 포함하여, 사람 스탄니오칼신-알파 폴리펩타이드의 저발현과 관련된 질환 또는 질환에 대한 민감성을 진단하는 방법.Low expression of a human staniocalcin-alpha polypeptide, comprising separating a nucleic acid sequence encoding human staniocalcin-alpha from a host-derived sample and measuring a mutation in the human staniocalcin-alpha nucleic acid sequence A method for diagnosing susceptibility to a disease or disorder associated with a disease. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019970703099A 1994-11-10 1994-11-10 Polypeptide with human Staniocalcin-alpha activity and pharmaceutical composition comprising the same KR100432260B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1994/013206 WO1996015147A1 (en) 1994-11-10 1994-11-10 Human stanniocalcin-alpha

Publications (2)

Publication Number Publication Date
KR970707155A true KR970707155A (en) 1997-12-01
KR100432260B1 KR100432260B1 (en) 2004-09-16

Family

ID=22243284

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970703099A KR100432260B1 (en) 1994-11-10 1994-11-10 Polypeptide with human Staniocalcin-alpha activity and pharmaceutical composition comprising the same

Country Status (6)

Country Link
EP (1) EP0797592A4 (en)
JP (1) JPH10509036A (en)
KR (1) KR100432260B1 (en)
AU (1) AU687962B2 (en)
NZ (1) NZ277605A (en)
WO (1) WO1996015147A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008322A (en) * 1996-04-02 1999-12-28 Zymogenetics, Inc. Stanniocalcin-2
US6538119B2 (en) * 1997-11-18 2003-03-25 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
ES2288016T3 (en) * 1998-04-10 2007-12-16 Daiichi Sankyo Company, Limited HUMAN STAYCALCINE AND USES OF THE SAME TO INHIBIT ADIPOGENESIS.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003949A1 (en) * 1986-11-21 1988-06-02 Howard Florey Institute Of Experimental Physiology The cs protein of the corpuscles of stannius
US5837498A (en) * 1994-03-08 1998-11-17 Human Genome Scienes, Inc. Corpuscles of stannius protein, stanniocalcin

Also Published As

Publication number Publication date
WO1996015147A1 (en) 1996-05-23
EP0797592A1 (en) 1997-10-01
AU1289695A (en) 1996-06-06
KR100432260B1 (en) 2004-09-16
NZ277605A (en) 1999-03-29
EP0797592A4 (en) 1999-10-20
JPH10509036A (en) 1998-09-08
AU687962B2 (en) 1998-03-05

Similar Documents

Publication Publication Date Title
JP2000060580A (en) Homolog tl5 of tnf
JPH11279196A (en) Vanilrep1 polypeptide and vanilrep1 polynucleotide
JP2003527067A (en) ACRP30R1L, a homologue of ACRP30 (30 KD adipocyte complement-related protein)
JP2005512515A5 (en)
KR970705635A (en) Human chemokine beta-9
JP2003024085A (en) Tumor necrosis-related receptor tr7
JPH08502164A (en) Opioid receptor gene
JP2000083689A (en) Sialoadhesin family member-2 (saf-2)
US20030118579A1 (en) Sparc-related proteins
JP2000506745A (en) New compound
US20080318835A1 (en) Novel Integrin Ligand ITGL-TSP
KR970707155A (en) Human stanniocalcin-alpha
JPH11183A (en) Polynucleotide of rat cathepsin k and polypeptide sequence
JP2005528080A5 (en)
JP4360902B2 (en) Fusion protein
Bruun et al. Serum amyloid A protein in mink during endotoxin induced inflammation and amyloidogenesis
JPH1118784A (en) Novel integrin ligand itgl-tsp
JP2004533235A5 (en)
JP2002300891A (en) New compound
CN1157406C (en) Novel, ATP-sensitive potassium-channel proteins and genes for the same
CA2215350A1 (en) Transforming growth factor alpha hii
JPH10304883A (en) New compound
WO2001046414A1 (en) Novel guanosine triphosphate-binding protein-coupled receptor protein, bg26
JP2004041175A (en) Human lig-1 homolog (hlig-1)
JP2000083683A (en) Frzb family member, frazzled

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20110428

Year of fee payment: 8

LAPS Lapse due to unpaid annual fee